doxepin + metamizole

Dolamizol is a fixed-dose combination of the tricyclic antidepressant doxepin and the non-opioid analgesic metamizole. Developed by Radboud University Medical Center, it is specifically designed to address the complex, often refractory pain associated with chronic pancreatitis. Doxepin contributes to the combination's efficacy by inhibiting the reuptake of serotonin and norepinephrine and acting as a potent histamine receptor antagonist, thereby modulating neuropathic pain pathways. Metamizole provides analgesic, antipyretic, and spasmolytic effects, likely through the inhibition of prostaglandin synthesis and interaction with the endocannabinoid system. This dual-action approach aims to provide superior pain relief compared to monotherapy for patients with chronic pancreatitis, a condition where traditional analgesics often fail.

Brand names

Dolamizol

Other names

doxepin/metamizole